A ferry protein in the pancreas protects it from the stress induced by a high-fat diet

September 16, 2020

Every time we eat, the glucose level in our body goes up. This spurs our pancreatic machinery into action and through intricate physiological mechanisms, appropriate amounts of insulin are produced, our blood glucose levels are controlled, and we remain healthy. But when a person indulges in high-fat food repeatedly over the long term, their pancreas is consistently overstimulated, eventually contributing to its damage and impairing its function. This increases the risk of developing type 2 diabetes, in which glucose level control mechanisms become lopsided.

Today, high-fat foods have become commonplace and so has diabetes. The need for designing new treatment strategies against diabetes is peaking. But to find an effective therapy, clarifying the causal cellular mechanisms at the core is essential. Now, a group of researchers from Japan, led by Dr Shoen Kume from Tokyo Institute of Technology (Tokyo Tech), have unraveled one key mechanism by which pancreatic function is regulated. Their findings are published in American Diabetes Association's journal Diabetes.

The pancreas contains "beta cells", which secrete excess insulin in response to excess glucose and fatty acid in the diet. Dopamine, or the "feel-good" hormone that is commonly known to induce feelings of pleasure, is what controls insulin levels, when excess insulin is produced. In the pancreas, a protein called VMAT2 ferries dopamine into sacs called "vesicles" to protect it from degradation by monoamine oxidase (MAO). The dopamine stored in vesicles is then released along with the insulin into the extracellular space of beta cells, where it binds to its specific receptor on the plasma membrane of the beta cells and acts as a brake for insulin secretion. Thus, through the modulation of dopamine, VMAT2 regulates pancreatic insulin levels as well.

Meanwhile, the degradation of dopamine by MAO produces a type of chemical called "reactive oxygen species", which when generated in excess, damages the beta cells.

But how do all these dots connect? "We wanted to understand the exact mechanism by which VMAT2 and dopamine signaling regulate beta cell function and glucose homeostasis" Dr Kume says.

To this end, Dr Kume and team created a genetically mutant mouse model, the beta cells of which would be deficient in the VMAT2 protein: the "βVmat2KO" mouse. They then ran experiments in which they fed these and wild type mice both a regular diet and a high-fat diet and monitored subsequent changes in their beta cell structure and function over the weeks that followed. In the immediate aftermath of being fed, the βVmat2KO mice, as expected, showed increased insulin secretion. But with prolonged exposure to a high-fat diet, they showed both impaired glucose and insulin tolerance and beta cell failure.

This prompted the researchers to infer the following: a high glucose and fat diet induces the simultaneous increase in insulin and dopamine production. But when VMAT2 is missing from the beta cell, the dopamine remains exposed to MAO and is degraded by it. However, as the amount of dopamine increases, its reaction with MAO rapidly produces the reactive oxygen species hydrogen peroxide. Over time, this constant oxidative stress leads to beta cell loss and failure. Thus, a high-fat diet accelerates beta cell failure and could cause the βVmat2KO mice to develop diabetes as they get older.

In this scenario, VMAT2 protects beta cells from the oxidative stress that a high fat diet induces in patients with diabetes.

"We were excited to discover that VMAT2, the protein widely known for its crucial role in dopamine transport and storage within pancreatic beta cells, also performs such a critical role in the cell's response to excess nutrition, such as a high-fat diet," Dr Kume says. "Our findings underscore the possibility of using VMAT2 as a target for novel therapeutic approaches against diabetes."

Tokyo Institute of Technology

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.